Abstract
Although Hox genes have been identified as master regulatory genes controlling embryonic development, an alternative view on the role of the Hox gene network suggests that it regulates crucial processes at cellular level in eukaryotic organisms. The Hox network acts at the nuclear cell level as a decoding system for external inductive signals to activate specific genetic programs. Cancer can be considered as an anomalous structure growing inside the human body and following, from an architectural viewpoint, the rules controlling body shape as occurs during embryonic development. As a consequence of this viewpoint, it has been proposed that the whole HOX gene network is involved in controlling phenotype cell identity and three-dimensionality of tissues and organs and, furthermore, that specific HOX genes or groups of genes are implicated in the neoplastic alterations of organs and tissues such as kidney, colon, lung, skin, bladder, breast, prostate. Despite our limited understanding of the mechanisms involved, it has already been possible to identify the specific HOX genes perturbed in certain types of human cancers with greater benefit for cancer patients than for better known oncogenes. Here we foresee the start of clinical trials with the purpose of targeting specific HOX genes in order to achieve a therapeutic effect in cancer patients.
Keywords: Tritorax genes, Antisense oligonucleotides, Kidney Cancer, Breast Cancer, RNA interference (RNAi)
Current Cancer Therapy Reviews
Title: The HOX Gene Network as a Potential Target for Cancer Therapy
Volume: 3 Issue: 1
Author(s): Monica Cantile, Giulia Schiavo, Luigi Terracciano and Clemente Cillo
Affiliation:
Keywords: Tritorax genes, Antisense oligonucleotides, Kidney Cancer, Breast Cancer, RNA interference (RNAi)
Abstract: Although Hox genes have been identified as master regulatory genes controlling embryonic development, an alternative view on the role of the Hox gene network suggests that it regulates crucial processes at cellular level in eukaryotic organisms. The Hox network acts at the nuclear cell level as a decoding system for external inductive signals to activate specific genetic programs. Cancer can be considered as an anomalous structure growing inside the human body and following, from an architectural viewpoint, the rules controlling body shape as occurs during embryonic development. As a consequence of this viewpoint, it has been proposed that the whole HOX gene network is involved in controlling phenotype cell identity and three-dimensionality of tissues and organs and, furthermore, that specific HOX genes or groups of genes are implicated in the neoplastic alterations of organs and tissues such as kidney, colon, lung, skin, bladder, breast, prostate. Despite our limited understanding of the mechanisms involved, it has already been possible to identify the specific HOX genes perturbed in certain types of human cancers with greater benefit for cancer patients than for better known oncogenes. Here we foresee the start of clinical trials with the purpose of targeting specific HOX genes in order to achieve a therapeutic effect in cancer patients.
Export Options
About this article
Cite this article as:
Cantile Monica, Schiavo Giulia, Terracciano Luigi and Cillo Clemente, The HOX Gene Network as a Potential Target for Cancer Therapy, Current Cancer Therapy Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339407780126593
DOI https://dx.doi.org/10.2174/157339407780126593 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Ocean to Bedside: the Therapeutic Potential of Molluscan Hemocyanins
Current Medicinal Chemistry Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: SOD Enzymes and Their Mimics in Cancer: Pro- vs Anti-Oxidative Mode of Action-Part I (Guest Editor: Ines Batinic-Haberle)]
Anti-Cancer Agents in Medicinal Chemistry Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry Therapeutic Strategies in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)
Central Nervous System Agents in Medicinal Chemistry Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship
Reviews on Recent Clinical Trials Twenty-Eight Years Survival with Metastatic Phaeochromocytoma Treated by Repeated [131I] Metaiodobenzylguanidine Therapy
Current Radiopharmaceuticals Application of Chiral α-Monofluorocarbonyl Compounds to Analytical and Medicinal Chemistry
Current Organic Chemistry Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Proteomics Interaction of Macrocyclic Lactones with the Multidrug Transporters: The Bases of the Pharmacokinetics of Lipid-Like Drugs
Current Drug Metabolism Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry LPTS: A Novel Tumor Suppressor Gene and a Promising Drug Target for Cancer Intervention
Recent Patents on Anti-Cancer Drug Discovery Inhibition of STAT Signalling in Bladder Cancer by Diindolylmethane - Relevance to Cell Adhesion, Migration and Proliferation
Current Cancer Drug Targets Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design Dynamic Contrast-Enhanced MRI in Oncology Drug Development
Current Clinical Pharmacology